Kalaris Therapeutics
KLRS
84 hedge funds and large institutions have $329M invested in Kalaris Therapeutics in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 27 reducing their positions, and 12 closing their positions.
102% more call options, than puts
Call options by funds: $647K | Put options by funds: $321K
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
6% more funds holding
Funds holding: 79 → 84 (+5)
0.01% less ownership
Funds ownership: 1.71% → 1.7% (-0.01%)
7% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 27
49% less capital invested
Capital invested by funds: $640M → $329M (-$311M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.16M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$6.61M |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$3.94M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$2.21M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$7.51M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.72M |
| 3 |
Alkeon Capital Management
New York
|
-$6.61M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.13M |
| 5 |
JP Morgan Chase
New York
|
-$3.01M |
KLRS Hedge Fund Activity: Q4 2021 in Review
84 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2021, worth a combined $329M — down 49% from $640M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KLRS positions and 12 closed out — a net gain of 6 holders — while 25 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $7.16M. The largest seller was Woodline Partners, cutting an estimated $7.51M.
- 84 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2021, up from 79 in Q3 2021.
- Funds reported $329M of Kalaris Therapeutics stock for Q4 2021, down 49% quarter-over-quarter.
- 18 funds opened new Kalaris Therapeutics positions in Q4 2021 and 12 closed out, a net change of +6 holders.
- The largest Kalaris Therapeutics buyer in Q4 2021 was BlackRock, an estimated $7.16M added.
- The largest Kalaris Therapeutics seller in Q4 2021 was Woodline Partners, an estimated $7.51M sold.
Based on aggregated 13F filings for Q4 2021.